Filana Therapeutics Statistics
Total Valuation
FLNA has a market cap or net worth of $61.83 million. The enterprise value is -$23.29 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FLNA has 48.31 million shares outstanding. The number of shares has increased by 1.39% in one year.
| Current Share Class | 48.31M |
| Shares Outstanding | 48.31M |
| Shares Change (YoY) | +1.39% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.74% |
| Owned by Institutions (%) | 28.36% |
| Float | 45.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19
| Current Ratio | 2.19 |
| Quick Ratio | 2.16 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -79.59% and return on invested capital (ROIC) is -29.80%.
| Return on Equity (ROE) | -79.59% |
| Return on Assets (ROA) | -23.40% |
| Return on Invested Capital (ROIC) | -29.80% |
| Return on Capital Employed (ROCE) | -68.38% |
| Weighted Average Cost of Capital (WACC) | 0.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.90M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.84% in the last 52 weeks. The beta is -0.76, so FLNA's price volatility has been lower than the market average.
| Beta (5Y) | -0.76 |
| 52-Week Price Change | -26.84% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 2.42 |
| Relative Strength Index (RSI) | 29.98 |
| Average Volume (20 Days) | 453,266 |
Short Selling Information
The latest short interest is 6.93 million, so 14.34% of the outstanding shares have been sold short.
| Short Interest | 6.93M |
| Short Previous Month | 7.24M |
| Short % of Shares Out | 14.34% |
| Short % of Float | 15.37% |
| Short Ratio (days to cover) | 19.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | -26.59M |
| Operating Income | -46.67M |
| Pretax Income | -77.90M |
| Net Income | -77.90M |
| EBITDA | -45.72M |
| EBIT | -46.67M |
| Earnings Per Share (EPS) | -$1.61 |
Full Income StatementBalance Sheet
The company has $86.57 million in cash and n/a in debt, with a net cash position of $86.57 million or $1.79 per share.
| Cash & Cash Equivalents | 86.57M |
| Total Debt | n/a |
| Net Cash | 86.57M |
| Net Cash Per Share | $1.79 |
| Equity (Book Value) | 68.14M |
| Book Value Per Share | 1.41 |
| Working Capital | 47.85M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 950,000 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
